# Iqvia Holdings Inc.: overview

IQV · NYSE · CIK 1478242 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/iqv.md) · [Financials](/companies/iqv/financials.md) · [Filings](/companies/iqv/filings.md) · [Insiders](/companies/iqv/insiders.md)

Latest reported revenue: [$4.43bn](/filings/0001628280-26-067646.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 27, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-067646).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3,958 d](/filings/0001628280-26-008322.md) | [3,829](/filings/0001628280-26-030675.md) | [4,017](/filings/0001628280-26-050211.md) | [4,100](/filings/0001628280-26-067646.md) | [4,364 d](/filings/0001628280-26-008322.md) | [4,151](/filings/0001628280-26-030675.md) | [4,368](/filings/0001628280-26-050211.md) | [4,428](/filings/0001628280-26-067646.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [15.8% d](/filings/0001628280-26-008322.md) | [13.0%](/filings/0001628280-26-030675.md) | [12.6%](/filings/0001628280-26-050211.md) | [13.5%](/filings/0001628280-26-067646.md) | [14.4% d](/filings/0001628280-26-008322.md) | [12.4%](/filings/0001628280-26-030675.md) | [11.6%](/filings/0001628280-26-050211.md) | [12.9%](/filings/0001628280-26-067646.md) |
| Net margin | % | [11.0% d](/filings/0001628280-26-008322.md) | [6.5%](/filings/0001628280-26-030675.md) | [6.6%](/filings/0001628280-26-050211.md) | [8.1%](/filings/0001628280-26-067646.md) | [11.8% d](/filings/0001628280-26-008322.md) | [6.6%](/filings/0001628280-26-030675.md) | [5.9%](/filings/0001628280-26-050211.md) | [7.9%](/filings/0001628280-26-067646.md) |
| Diluted EPS | $ per share | not reported | [1.40](/filings/0001628280-26-030675.md) | [1.54](/filings/0001628280-26-050211.md) | [1.93](/filings/0001628280-26-067646.md) | not reported | [1.61](/filings/0001628280-26-030675.md) | [1.53](/filings/0001628280-26-050211.md) | [2.10](/filings/0001628280-26-067646.md) |
| Free cash flow | $m | [721 d](/filings/0001628280-26-008322.md) | [426](/filings/0001628280-26-030675.md) | [292 d](/filings/0001628280-26-050211.md) | [772 d](/filings/0001628280-26-067646.md) | [561 d](/filings/0001628280-26-008322.md) | [491](/filings/0001628280-26-030675.md) | [360 d](/filings/0001628280-26-050211.md) | [667 d](/filings/0001628280-26-067646.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [13.9](/filings/0001478242-24-000038.md) | [14.4](/filings/0001478242-25-000045.md) | [15.0](/filings/0001628280-26-008322.md) | [15.4](/filings/0001628280-26-008322.md) | [16.3](/filings/0001628280-26-008322.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [10.0%](/filings/0001478242-24-000038.md) | [12.5%](/filings/0001478242-25-000045.md) | [13.2%](/filings/0001628280-26-008322.md) | [14.3%](/filings/0001628280-26-008322.md) | [13.4%](/filings/0001628280-26-008322.md) |
| Net margin | % | [7.0%](/filings/0001478242-24-000038.md) | [7.6%](/filings/0001478242-25-000045.md) | [9.1%](/filings/0001628280-26-008322.md) | [8.9%](/filings/0001628280-26-008322.md) | [8.3%](/filings/0001628280-26-008322.md) |
| Diluted EPS | $ per share | [4.95](/filings/0001478242-24-000038.md) | [5.72](/filings/0001478242-25-000045.md) | [7.29](/filings/0001628280-26-008322.md) | [7.49](/filings/0001628280-26-008322.md) | [7.84](/filings/0001628280-26-008322.md) |
| Free cash flow | $bn | [2.3](/filings/0001478242-24-000038.md) | [1.6](/filings/0001478242-25-000045.md) | [1.5](/filings/0001628280-26-008322.md) | [2.1](/filings/0001628280-26-008322.md) | [2.1](/filings/0001628280-26-008322.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/iqv/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $2.81bn | 14,549,693 |  | Reduced −477,751 |
| [HARRIS ASSOCIATES L P](/funds/813917.md) | 2026-06-30 | $2.35bn | 12,183,830 |  | Added +555 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.11bn | 10,905,053 |  | Reduced −121,930 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.45bn | 7,508,244 |  | Added +31,282 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.45bn | 7,501,993 |  | Reduced −74,008 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $1.19bn | 6,139,775 |  | Added +732,085 |
| [Artisan Partners Limited Partnership](/funds/1466153.md) | 2026-06-30 | $916.5m | 4,743,434 |  | Reduced −315,431 |
| [Boston Partners](/funds/1386060.md) | 2026-06-30 | $865.5m | 4,466,016 |  | Added +227,058 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $857.2m | 4,454,134 |  | Reduced −8,918 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $632.8m | 3,275,141 |  | Added +13,363 |

## Recent filings

[All 1,074 filings](/companies/iqv/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-27 | 17:07 ET | [10-Q](/filings/0001628280-26-067646.md) | Quarterly report, period 2026-09-30 | 0001628280-26-067646 |
| 2026-10-27 | 07:08 ET | [8-K](/filings/0001628280-26-067406.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-067406 |
| 2026-09-23 | 17:03 ET | [8-K](/filings/0001193125-26-399616.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-399616 |
| 2026-09-09 | 17:21 ET | [8-K](/filings/0001193125-26-386633.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-386633 |
| 2026-07-28 | 16:38 ET | [10-Q](/filings/0001628280-26-050211.md) | Quarterly report, period 2026-06-30 | 0001628280-26-050211 |
| 2026-07-28 | 07:03 ET | [8-K](/filings/0001628280-26-049923.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-049923 |
| 2026-06-11 | 16:46 ET | [8-K](/filings/0001193125-26-267763.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-267763 |
| 2026-06-04 | 17:08 ET | [8-K](/filings/0001193125-26-257730.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-257730 |
| 2026-06-03 | 16:45 ET | [8-K](/filings/0001193125-26-255635.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-255635 |
| 2026-05-07 | 17:24 ET | [8-K](/filings/0001193125-26-212463.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-212463 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-008322.md), filed Feb 17, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1478242
- Tickers: IQV
- Exchange: NYSE
- SIC code: 8731 Services-Commercial Physical & Biological Research
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 22:09 ET. No prices; not investment advice.